**Division of Cutaneous Oncology**

**Initial Visit**

**History of Present Illness:** @NAME@ is a @AGE@ @SEX@ who presents for initial consultation for suspected \*\*\*(CTCL type suspected), referred by \*\*\*.

**Narrative HPI**: \*\*\*

**Registry:**

|  |  |
| --- | --- |
| **Date of initial visit** with CTCL specialist |  |
| **Date of onset** of skin lesions  (month/year) |  |
| **Initial symptoms** at presentation  (itching 1-10, flaking/scaling, color change) |  |
| **Initial lesion type**  (patch, plaque, tumor, erythroderma) |  |
| **Initial quantity** of lesions  (single, multiple, unknown) |  |
| **Initial location** of lesions  (where anatomically located) |  |
| **Prior diagnosis** for CTCL lesions  (psoriasis, eczema, etc.) |  |
| **Prior treatments** for CTCL lesions  (name, date started/stopped, reason for stopping, dose, response) |  |
| **Prior skin biopsies**  (dates / result) |  |
| **Disease course** since lesion onset  (clearance, progression, relapse) |  |
| **Medication changes** prior to lesion onset  (If yes, specify) |  |
| **Exposures** from travel, recreation, occupation, or environment prior to lesions  (industrial, pesticides, pollution, etc.) |  |
| **Current symptoms**  (itching 1-10, flaking/scaling, color change) |  |
| **Current treatments**  (date started, dose, response) |  |
| **Current location** of lesions  (where anatomically located) |  |

**Patient History**

@ALLERGIES@

@PASTMEDICAL@

@PASTSURGICAL@

@FAMILYHISTORY@

@SOCIALHISTORY@

**@ROS@**

As noted in the HPI.

**Physical Exam**

@VITALSALL@

General: the patient is overall well appearing

Neuro: the patient is alert and oriented

Mood: appropriate

TBSE including mucosal surfaces was performed. Notable findings:

Scalp/Hair: No lesions suspicious for malignancy.

Head/Face: No lesions suspicious for malignancy.

Conjunctiva/Lids: No lesions suspicious for malignancy.

Lips: No lesions suspicious for malignancy.

Oral mucosa: No lesions suspicious for malignancy.

Teeth: No lesions suspicious for malignancy.

Neck: No lesions suspicious for malignancy.

Chest: No lesions suspicious for malignancy.

Breasts/Axillae: No lesions suspicious for malignancy.

Abdomen: No lesions suspicious for malignancy.

Genitalia: No lesions suspicious for malignancy.

Back: No lesions suspicious for malignancy.

Buttocks: No lesions suspicious for malignancy.

RUE: No lesions suspicious for malignancy.

LUE: No lesions suspicious for malignancy.

RLE: No lesions suspicious for malignancy.

LLE: No lesions suspicious for malignancy.

Digits/Nails: No lesions suspicious for malignancy.

General Exam

Lymph: no palpable lymph nodes\*\*\*

Peripheral vascular: warm and well perfused

Edema/Varicosities: no peripheral edema

Eccrine, apocrine glands: unremarkable

TBSA \*\*\*, mSWAT \*\*\*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Body Region** | % BSA for this Region | % BSA as Patch | % BSA as Plaque | % BSA as Tumor |
| Head | 7% |  |  |  |
| Neck | 2% |  |  |  |
| Anterior trunk | 13% |  |  |  |
| Arms | 8% |  |  |  |
| Forearms | 6% |  |  |  |
| Hands | 5% |  |  |  |
| Posterior trunk | 13% |  |  |  |
| Buttocks | 5% |  |  |  |
| Thighs | 19% |  |  |  |
| Legs | 14% |  |  |  |
| Feet | 7% |  |  |  |
| Groin | 1% |  |  |  |
| **% BSA by category** | 100% |  |  |  |
| **Severity Weighting Factor** |  | x1 | x2 | x4 |
| **Skin Score Total** |  |  |  |  |
| **mSWAT** |  | | | |

PATHOLOGY, IMAGING AND LABORATORY DATA:

All internal, external data were directly reviewed and summarized below.

**LABORATORY**:

**FLOW CYTOMETRY:**

**PATHOLOGY**:

**IMAGING**:

**ASSESSMENT**:

**PLAN**:

@NAME@ is a @AGE@ @SEX@ with stage \*\*\*. Today patient with \*\*\* TBSA involvement, mSWAT \*\*\* with \*\*\*

@CTCLEXPLANATION@

@TREATMENTPLAN@

**Prognostic index (Choose Early versus Late)**

**Early CLIPI Prognostic Index**

|  |  |
| --- | --- |
|  | **Points (1 each)** |
| Male |  |
| Age > 60 |  |
| Plaques |  |
| Folliculotropic |  |
| N1/Nx |  |
| **Total Points** | \*\*\*/5 |

**Risk Group**: \*\*\*

Group 1 (1 risk factor); Group 2 (2 risk factors); Group 3 (3+ risk factors)

Reference: Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859-2868. doi:10.1016/j.ejca.2013.04.018

**Late CLIPI Prognostic Index**

|  |  |
| --- | --- |
|  | **Points (1 each)** |
| Male |  |
| Age > 60 |  |
| B1/B2 |  |
| N2/3 |  |
| Visceral involvement |  |
| **Total Points** | \*\*\*/5 |

**Risk Group**: \*\*\*

Group 1 (1 risk factor); Group 2 (2 risk factors); Group 3 (3+ risk factors)

Reference: Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859-2868. doi:10.1016/j.ejca.2013.04.018

@FOLLOWUP@